SCHEMBL1493341

SCHEMBL1493341

COc1ccc(Cn2nccc2NC(=O)CSc2nnnn2-c2cccc(OC)c2)cc1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.62
LMNA P02545 3/20 0.62
TSHR P16473 4/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
ESR1 P03372 1/20 0.61
POLB P06746 1/20 0.59
MAPT P10636 2/20 0.57
MAPK1 P28482 1/20 0.57
HPGD P15428 2/20 0.57
RECQL P46063 1/20 0.57
USP2 O75604 1/20 0.57
NTRK1 P04629 1/20 0.57
NTRK2 Q16620 1/20 0.57
HTT P42858 1/20 0.57
CYP1A2 P05177 1/20 0.57
CYP3A4 P08684 1/20 0.57
CYP2D6 P10635 1/20 0.57
CYP2C19 P33261 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1611516 0.95 ALDH1A1 (0.56) ALDH1A1LMNATSHRSMN1; SMN2ESR1
SCHEMBL1493500 0.94 ALDH1A1 (0.56) ALDH1A1LMNATSHRSMN1; SMN2ESR1
SCHEMBL1612297 0.94 ALDH1A1 (0.54) ALDH1A1LMNATSHRSMN1; SMN2ESR1
SCHEMBL1611132 0.93 ALDH1A1 (0.67) ALDH1A1LMNASMN1; SMN2POLBMAPK1
SCHEMBL1493461 0.90 CYP1A2 (0.54) ALDH1A1LMNASMN1; SMN2MAPTMAPK1
SCHEMBL1493382 0.89 CYP1A2 (0.60) ALDH1A1LMNASMN1; SMN2MAPTMAPK1
SCHEMBL1493369 0.89 ALDH1A1 (0.56) ALDH1A1LMNASMN1; SMN2MAPK1USP2
SCHEMBL1493372 0.88 ALDH1A1 (0.55) ALDH1A1LMNATSHRSMN1; SMN2MAPK1
SCHEMBL1610964 0.87 ALDH1A1 (0.61) ALDH1A1LMNATSHRSMN1; SMN2MAPT
SCHEMBL1610520 0.87 ALDH1A1 (0.54) ALDH1A1LMNAMAPK1NTRK1NTRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110086889-A1 TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-04-14 US claimed
US-20110086889-A1 TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-04-14 US disclosed
EP-2288603-A1 TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS Actelion Pharmaceuticals Ltd. (CH) 2011-03-02 EP disclosed
WO-2009150614-A1 TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110086889-A1 TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPY1R ALDH1A1 3233/4885LMNA 4145/4885TSHR 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.